To collect and characterise the incidence of adverse events related to the safety specifications*1 of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.~This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.~*1: Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.